Foghorn Therapeutics Inc.
FHTX
$5.41
-$0.12-2.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -17.94M | -18.83M | -19.50M | -19.12M | -22.98M |
| Total Depreciation and Amortization | 851.00K | 827.00K | 761.00K | 733.00K | 791.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.81M | 3.32M | 2.34M | 2.62M | 6.31M |
| Change in Net Operating Assets | -7.72M | -9.28M | -8.12M | -5.23M | -9.66M |
| Cash from Operations | -21.00M | -23.97M | -24.52M | -21.01M | -25.54M |
| Capital Expenditure | -22.00K | -28.00K | -479.00K | -309.00K | -17.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 33.86M | 29.43M | 22.77M | -61.01M | -17.96M |
| Cash from Investing | 33.83M | 29.40M | 22.29M | -61.32M | -17.98M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 254.00K | 139.00K | 4.00K | 1.44M | 103.40M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | -390.00K | -195.00K |
| Cash from Financing | 254.00K | 139.00K | 4.00K | 1.05M | 103.21M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 13.09M | 5.57M | -2.22M | -81.27M | 59.69M |